Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

14    Boehringer Ingelheim    $7.0B    up 9.4%
Global revenue*: $16.5B (14th); down 1.2%

R&D spend*: $3.3B (13th), up 2.0%; 19.8% of rev.

Top brands: Spiriva ($2.4B), Combivent ($1.1B),  Pradaxa ($559M), Aggrenox ($471M), Fluticasone ($352M)

Planned launches: Afatinib (onc.), Vargatef (onc.), volasertib (onc.), BI 10773 (diab.)

Promotional spend: $906M (8th); 12.9% of rev.

Patent expirations: Spiriva Handihaler (2018)

Boehringer Ingelheim is firing on all cylinders, with six products planned to launch over the next two years, the global roll-out of Pradaxa under way and scarcely a patent expiration in sight. The company has a host of oncology and hepatitis C virus treatments in late-stage clinical trials (BI201335/BI207127), and its partnership with Lilly is already bearing fruit on the diabetes front, with Jentadueto having followed Tradjenta to market. The firm has just completed a $350-million expansion in the US, which accounts for 45% of sales. Blood thinner Pradaxa now must fend off competition from J&J/Bayer Xarelto, and maybe soon Pfizer/BMS drug Eliquis (apixaban).
*Global revenue and R&D spend are based on the 2010 financial year, the latest data available at press time.

Back to first page

Page 14 of 21
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.